Elicera Therapeutics
Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research
The research grant from the Swedish Childhood Cancer Fund is awarded to Uppsala University, and the results generated in the project will contribute to the understanding of whether Elicera's cell therapy candidate ELC-401 could also be used in the future to treat brain tumors in children.
"We are very pleased that the Swedish Childhood Cancer Fund has given our co-founder Magnus Essand the confidence to continue developing his groundbreaking research at Uppsala University. The possibility of developing our cell therapy candidate ELC-401 in the future for the treatment of children with brain tumors is very interesting, and the size of the grant is a clear testament to the importance of Magnus Essand's contributions to cancer research and the potential of Elicera's development projects," says Jamal El-Mosleh, CEO of Elicera Therapeutics.
| Datum | 2023-12-22, kl 13:47 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!